David A. Wohl, MD Professor of Medicine Site Leader, Global HIV Prevention & Treatment Research Site Co-Director, North Carolina AIDS Training & Education Center Co-Director, Viral Hemorrhagic Fever Clinical Research Group Institute for Global Health & Infectious Diseases The University of North Carolina (UNC) at Chapel Hill School of Medicine Chapel Hill, NC

Carlos Malvestutto, MD, MPH Assistant Professor Division of Infectious Diseases Ohio State University Wexner Medical Center Columbus, OH

Jaimie P. Meyer, MD, MS, FACP Assistant Professor of Medicine Department of Internal Medicine, Section of Infectious Disease AIDS Program Yale University School of Medicine Clinical Assistant Professor Division of Primary Care/Health Systems in Nursing Yale School of Nursing New Haven, CT

Statement of Need

Injection drug use (IDU) has been fueled by the opioid crisis, resulting in a dramatic increase in hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections. People with opioid use disorder (OUD) are 28 times more likely to contract HIV, and one in 10 new HIV infections is attributed to IDU. Further, the CDC reported a 233% increase in new HCV infections between 2010-2016.

Although effective treatments for HIV and HCV exist and are readily available, barriers related to OUD make treatment difficult in this population, especially in the rural, correctional, and VA settings.

In this CME Outfitters Live and On Demand, expert faculty discuss strategies for HIV and HCV testing in special OUD populations, applying evidence-based treatment approaches, as well as prevention strategies, including PrEP, for patients with OUD at high risk for HIV infection.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Implement strategies for HIV and HCV testing in special OUD populations in correctional, VA, and rural settings.
• Apply evidence-based treatment approaches in patients with OUD with HIV or HCV infection or HIV/HCV co-infection.
• Identify patients with OUD at high risk for HIV infection who are candidates for HIV prevention strategies, including PrEP.

The following learning objectives pertain only to those requesting CNE or CPE credit:

• Discuss strategies for HIV and HCV testing in special OUD populations in correctional, VA, and rural settings.
• Describe evidence-based treatment approaches in patients with OUD with HIV or HCV infection or HIV/HCV co-infection.
  
• Identify patients with OUD at high risk for HIV infection who are candidates for HIV prevention strategies, including PrEP.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

OUD specialists, primary care physicians, psychiatrists, mental health specialists, physician assistants, nurse practitioners, nurses, and pharmacists.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-19-032-L01-P
Enduring: 0376-0000-19-032-H01-P

Type: Knowledge-based 

Note to ABPN Diplomates: ABPN Diplomates may select any activity relevant to their practice to count towards ABPN MOC requirements.

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity
Enduring material

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit^TM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), a 75% pass rate is required. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Wohl reports that he receives research support from Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare. He is on the advisory committee for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and ViiV Healthcare. He is a consultant for Gilead Sciences, Inc. 

Dr. Malvestutto reports that he serves on the advisory committee for ViiV Healthcare.

Dr. Meyer reports that she receives research support from Gilead Sciences, Inc.

Kavitha Ramachandran, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS(877.263.7767).

TV-104-091919-47